Weekly View

ICER Weekly View 03-24-17

From the desk of Mitchell Stein   Good morning. Today’s healthcare focus is centered on what will happen with the house vote on the AHCA. While outside the purview of this newsletter, I will point out that today’s manager’s amendment to allow states to redefine the essential health benefits package puts both prescription drug coverage […]

Read More

ICER Weekly View 03-17-17

From the desk of Mitchell Stein   Good morning and happy Saint Patrick’s Day! ☘️ So much news, so little time. Today we’ll look at: ICER in the News – ICER more transparent than NICE, update to ICER’s PCSK9 work, ICER recognizes the National MS Society with a leadership award, RA evidence report released, and new […]

Read More

ICER Weekly View 03-10-17

From the desk of Mitchell Stein   Good morning. This week’s dominant healthcare story, the release of the Republican ACA replacement bill, is beyond the scope of this blog (to get my reaction to that story, you’ll have to follow me on Twitter). However, we have a lot of pharma news to talk about. This […]

Read More

ICER Weekly View 03-03-17

From the desk of Mitchell Stein   Good morning. I hope everyone had a good week. As always, we have a lot to cover. Here are today’s categories and stories: ICER in the News – An interview with Dan Ollendorf, orphan drugs, value-framework revisions, ovarian cancer drug review, and release of New and Noteworthy Inside […]

Read More

ICER Weekly View 02-24-17

From the desk of Mitchell Stein   Good morning. Another week, another avalanche of news. I received some positive feedback regarding using sections to make things more manageable, so for now, we’ll stick with it. This week starting off with ICER in the News, followed by four subcategories under Pharmaceutical news. ICER in the News […]

Read More

ICER Weekly View 02-17-17

From the desk of Mitchell Stein   Good morning. In the week since we’ve talked, I’ve been buried both literally and figuratively. Here in Portland ME, we’ve had over 30 inches of snow this week, while nationally, the “news” just keeps on coming. To help with the volume, today I’ve divided our stories into four […]

Read More

ICER Weekly View 02-10-17

From the desk of Mitchell Stein   Good morning. Welcome to the new weekly version of this blog. To help navigate with the increased number of articles (although I promise, I’m trying not to go crazy), I’ve added subcategories to the Pharmaceutical News section. In addition to ICER in the News, today’s subsections include […]

Read More

Changes coming to Morning View

From the desk of Mitchell Stein   Starting this Friday, ICER Morning View will return in a new format, going from a daily brief on the news to a weekly review of top stories: The ICER Weekly View. I enjoy writing this combination blog and news digest, and over the past year, I’ve been humbled […]

Read More

Morning View 02-02-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. ICER announced proposed changes to our value assessment framework, links below to the announcement and some of the coverage. ICER was also mentioned in an opinion piece looking at possible improvements to current FDA processes. In Washington, Price’s nomination moved forward as […]

Read More

Morning View 02-01-17

From the desk of Mitchell Stein, Policy and Communications Director   Good morning. We’ll start with ICER news as a Takeda executive discusses us in an interview, and we post this month’s edition of New and Noteworthy. On the industry front, once again we start in DC with two big stories, the first is the […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP